<DOC>
	<DOCNO>NCT01550003</DOCNO>
	<brief_summary>A Multicenter , Open-label Study Assess Pharmacokinetics , Safety Efficacy Certolizumab Pegol Children Adolescents With Moderately Severely Active Polyarticular-course Juvenile Idiopathic Arthritis ( JIA ) .</brief_summary>
	<brief_title>Pediatric Arthritis Study Certolizumab Pegol</brief_title>
	<detailed_description>The overall study consist Screening Period 4 week Open-Label Treatment Period continue approval marketing application Polyarticular-course Juvenile Idiopathic Arthritis ( JIA ) indication subject 's country region notice UCB ( approximately 4-6 year duration ; depend region ) . A Final Visit conduct 12 week last dose study medication . Overall , study visit occur monthly first 6 month every 2 month afterwards . All patient receive active treatment Certolizumab Pegol . The dose depend actual weight . Home dosing allow study visit . If less 50 % study population achieve adequate response treatment ( American College Rheumatology Pediatric 30 % ( PedACR30 ) response ) Week 16 , study entirely discontinue .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Onset sign symptom consistent diagnosis Juvenile Idiopathic Arthritis ( JIA ) ( accord International League Associations Rheumatology Classification Juvenile Idiopathic Arthritis , 2001 ) initiation JIA treatment least 6 month prior Baseline ( Active Polyarticularcourse JIA disease define ≥ 5 joint active Arthritis include : Polyarticular Rheumatoid Factor ( RF ) positive , Polyarticular RFnegative , extend oligoarticular , Juvenile Psoriatic Arthritis enthesitisrelated Arthritis ) Children adolescent , age 2 17 year ( inclusive ) ; weight ≥ 10 kg Inadequate response intolerance least 1 DiseaseModifying Antirheumatic Drug ( DMARD ) ( previous exposure maximum 2 biologic agent allow ) Methotrexate ( MTX ) oral Corticosteroids allow stable dos prior Screening If use Methotrexate ( MTX ) , inadequate response intolerance MTX History systemic JIA , without systemic feature Active Uveitis history active Uveitis within precede 6 month Known history Tuberculosis ( TB ) , high risk acquire TB latent TB infection ; chronic , recurrent infection current sign symptom may indicate infection , high risk infection Viral Hepatitis Human Immunodeficiency Virus ( HIV ) infection ; live vaccination , include attenuate , within defined period prior study entry study ( nonlive vaccination permit time prior study ) The use , dose change , specific medication ( eg , nonbiologic DMARDs , biologic DMARDs , oral intramuscular/intravenous/intraarticular Corticosteroids ) allow define period time prior study entry Previous exposure Certolizumab Pegol ( CZP ) , 2 biologic DMARDs previous lack response 1 Tumor Necrosis Factor ( TNFα ) antagonist drug</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cimzia</keyword>
	<keyword>JIA</keyword>
	<keyword>Polyarticular</keyword>
	<keyword>Oligoarticular</keyword>
	<keyword>Enthesitis-related-Arthritis</keyword>
	<keyword>Juvenile Idiopathic Arthritis</keyword>
	<keyword>Juvenile Psoriatic Arthritis</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>PASCAL</keyword>
	<keyword>CDP870</keyword>
</DOC>